Alvotech to Present Switching Study Results of AVT02, a Proposed Biosimilar to Humira at ACR 2022
Shots:
- The company highlighted the 2 posters on the switching study for ATV02. The 1st poster highlighted the interchangeability b/w AVT02 and Humira. The 2nd poster highlighted ex vivo comparative immunogenicity assessment to assess immunogenicity in patients with chronic PsO
- The study focuses to determine the PK, immunogenicity, efficacy & safety in patients undergoing repeated switches b/w Humira and AVT02
- AVT02 is a mAb & was approved in the EU, the UK, Switzerland, Norway, Iceland, Lichtenstein & Canada. In Feb 2022, the US FDA accepted the BLA of ATV02 which incl. new data supporting interchangeability b/w ATV02 and Humira & is currently under the US FDA’s review
Ref: Globenewswire | Image: Alvotech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
